Singular Health Accelerates U.S. Rollout and Regulatory Wins as Imaging Platform Gains Traction

The latest announcement is out from Singular Health Group Ltd ( (AU:SHG) ).

Singular Health Group reported a quarter of strong operational progress, highlighted by the continued rollout of its Provider Network Solution (PNS) contract in the U.S., where deployment of an additional 500 3DICOM MD licences is underway and triggering a further US$500,000 payment, with early results indicating duplicate imaging reductions exceeding targets in a US$16.5 billion addressable market. The company advanced its Life Radiology pilot in Miami into full patient deployment, replacing CD-ROMs with cloud-based access via 3DICOM Patient using its MFTP protocol, while also pursuing major U.S. growth opportunities including a multi‑million‑dollar project request to the U.S. House of Representatives for a Florida Medicaid imaging repository, a separate MOU with Florida International University, and securing key regulatory milestones such as FDA 510(k) clearance for 3DICOM MD Cloud and ISO 13485 renewal, all supported by a cash runway of around eight quarters.

The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.

More about Singular Health Group Ltd

Singular Health Group Ltd is an Australian-listed medical imaging technology company that develops interoperable imaging software, including its 3DICOM suite and proprietary Medical File Transfer Protocol (MFTP), targeting U.S. and international healthcare providers, management services organisations and health plans to reduce duplicate imaging and modernise patient access to imaging data.

Average Trading Volume: 392,463

Technical Sentiment Signal: Buy

Current Market Cap: A$80.06M

See more data about SHG stock on TipRanks’ Stock Analysis page.